BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Dec 07, 2009
 |  BioCentury  |  Analyst Picks & Changes

Analyst Picks & Changes

Analyst Picks & Changes

Company Bank Analyst Coverage Opinion Wk chg 12/4 cls
Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) Roth Capital Partners Andrew Vaino Downgrade Hold (from buy) 4% $17.45
Vaino also lowered his target to $17 from $26 on slower than expected progress for Alnylam's lead compound, ALN-RSV01, to treat respiratory syncytial virus infection. He now expects the RSV specific short interfering RNA (siRNA) to enter Phase III testing in mid-2011 instead of 2010 and a market launch in 2015 instead of 2014. Vaino also lowered his potential market size estimate for ALN-RSV01 to <2,000 from >100,000 patients after the company said it will start a Phase IIb trial in adult lung transplant patients early next year instead of in the general RSV population as he had expected. Alnlylam was unchanged for the Thanksgiving holiday week ended Nov. 27, when Vaino issued his report.
Basilea Pharmaceutica AG (SIX:BSLN) UBS Guillaume van Renterghem Price target Buy 6% CHF83.95
van Renterghem lowered his target to CHF105 from CHF170. He noted that the antibacterials market has become "increasingly competitive" and reduced his sales estimates for Zevtera ceftobiprole to treat complicated skin and skin structure infections (cSSSIs). van Renterghem also lowered his probability for approval to treat cSSSIs to 70% from 80%, saying he thinks FDA is in "no rush" to approve Zevtera because the agency has not yet invited partner Johnson & Johnson (NYSE:JNJ) to an advisory committee to discuss the broad...

Read the full 1409 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >